PROCRIT® is indicated for the treatment of anemia due to zidovudine administered at ≤4,200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤500 mUnits/mL.
PROCRIT® has not been shown to improve quality of life, fatigue, or patient well-being.
PROCRIT® is not indicated for use:
Established dosing and titration for patients with HIV infection with anemia due to zidovudine1
at 100 U/kg
IV or SC, TIW
If Hb does not increase after 8 weeks,
INCREASE DOSE by 50 U/kg to 100 U/kg* at 4- to 8-week intervals until Hb reaches a level needed to avoid RBC transfusions or 300 U/kg
The PROCRIT® full Prescribing Information recommends that patients be titrated to achieve and maintain the lowest Hb level sufficient to avoid the need for blood transfusion and not to exceed the upper safety limit of 12 g/dL.
if Hb exceeds 12 g/dL
Resume therapy at a dose 25% below the previous dose when Hb declines to <11 g/dL
if an increase in Hb is not achieved at a dose of 300 U/kg for 8 weeks
Hb=hemoglobin; HIV=human immunodeficiency virus; IV=intravenously; SC=subcutaneously; TIW=3 times weekly; U=units.
PROCRIT® is contraindicated in patients with uncontrolled hypertension, pure red cell aplasia (PRCA) that begins after treatment with PROCRIT® or other erythropoietin protein drugs, or serious allergic reactions to PROCRIT®. PROCRIT® from multiple-dose vials contains benzyl alcohol and is contraindicated in neonates, infants, pregnant women, and lactating women.1 Please see the FULL PRESCRIBING INFORMATION to learn more.